NVE's CEO Discusses F1Q2013 Results - Earnings Call Transcript

NVE Corporation (NVEC)

F1Q 2013 Earnings Call

July 18, 2012 5:00 p.m. ET


Daniel Baker - President and CEO

Curt Reynders - CFO


Steven Crowley - Craig-Hallum Capital Group



Good day ladies and gentlemen and welcome to the NVE conference call of first quarter results. At this time all participants are in a listen-only mode. Later we will conduct a question and answer session and instructions will follow at that time. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to introduce your host for today’s conference Mr. Dan Baker. Please go ahead.

Daniel Baker

Good afternoon and welcome to our conference call for the quarter ended June 30 th 2012 which was the first quarter of fiscal 2013. As always, I am joined by Curt Reynders, our chief financial officer. This call is being webcast live and being recorded. A replay will be available through our website nve.com. After my opening comments, Curt will present a financial review of the quarter. I'll cover business items and we’ll open the call to questions.

In the past hour following the close of market, we filed our press release with quarterly results and our quarterly report on Form 10-Q with the SEC. The filings are available through our website or the SEC's website. Comments we may make that relate to future plans, events, financial results or performance are forward-looking statements that are subject to certain risks and uncertainties, including, among other such factors as risk in continued profitability, uncertainties relating to future revenue and growth, risks related to developing marketable products, uncertainties relating to the revenue potential of new products, risks of losses on our marketable securities, risks in the enforcement of our patents, litigation risks as well as the risk factors listed from time to time in our filings with the SEC, including our annual report on Form 10-K for the year ended March 31, 2012 as updated by our quarterly report on Form 10-Q filed this afternoon. The company undertakes no obligation to update forward-looking statements we may make.

We’re pleased to report strong earnings for the quarter and our highest first-quarter product sales ever. Product sales were $7.03 million, a slight increase over our record quarter a year ago. We had record gross pre-tax and net margins. Gross margin was a record 76% and net income was $0.69 per diluted share.

Now I’ll turn the call over to Curt for details of our financial results.

Curt Reynders

Thanks Dan. Total revenue for the first quarter of fiscal 2013 decreased 9% to $7.46 million due to a 64% decrease in contract research and development revenue, partially offset by a slight increase in product sales. Product sales increased a 10th of a percent from a record quarter a year ago to $7.03 million. The increase was due to increased sales into medical device markets, partially offset by decreased sales into industrial markets. Industrial markets may have been impacted by a sluggish global economy.

Growth in the medical device markets may have been tempered by softness of pacemakers and ICDs. The large percentage decrease in contract R&D was due to the completion of certain contracts and contract activities and the challenging government funding environment.

Contract R&D was 6% of total revenue and it is not a major part of our growth vision. Gross margin increased to a record 76% of revenue compared to 68% last year due to a more favorable revenue mix and more efficient product manufacturing. The more favorable revenue mix was a higher percentage of revenue from product sales compared to contract R&D and a more favorable product mix. The more efficient product manufacturing included manufacturing processes deployed late in the calendar year which we discussed in previous calls.

Total expenses increased 10% for the first quarter of fiscal 2013 compared to the prior year quarter due to a 39% increase in R&D expenditures partially offset by a 13% decrease in selling, general and administrative expense. The decrease in selling, general and administrative expense was due to a decrease in legal expenses. The first increase in research and development expense was due to increased product development activities. We believe the investment in R&D will pay off in future revenues. Dan will highlight R&D in a few minutes.

Income before taxes for the quarter was $5 million. Net income for the first quarter was $3.38 million or $0.69 per diluted share compared to $0.70 last year. Pre-tax and net margins were records. Pre-tax margin was 67% and net margin was 45%.

NVE ranked third in return on revenue or net margin in the Star Tribune's list of the 100 largest companies in Minnesota published in the past quarter. Operating cash flow was $4.1 million for the quarter, which strengthened our balance sheet. As of June 30, cash plus marketable securities was $77.1 million, an increase of $3.52 million in the quarter.

Despite widely publicized bond downgrades in the past quarter, our bond portfolio has performed well with a net unrealized gain on our marketable securities $1.57 million as of June 30, which is the difference between the fair market value of our portfolio and its adjusted cost. There are details in our recently filed 10-Q.

Income taxes payable increased $1.4 million, because we had no estimated income tax payments due in the most recent quarter. There are two payments due in the quarter ending September 30. Purchases of fixed assets were $445,000 for the quarter compared to $199,000 for the prior year quarter. Capital investments were primarily for production equipment as we continued to expand and upgrade our production capabilities to support potential new products and growth. We are planning additional facilities investments this quarter and in the remainder of the fiscal year.

Read the rest of this transcript for free on seekingalpha.com